Fig 3.
Average change in lesional size with time, relative to the initial treatment volume, separated by histopathology (radiosensitive: lung, breast, colon, other; radioresistant: melanoma, renal). Radiosensitive tumors were more likely to increase in size during the first 12–18 months post-SRS than radioresistant tumors. However, this difference did not extend, consistently, beyond 18 months.
